Technology overview

Our technique of intraoperative detection of tumors is based of the immunophotodetection (IPD) technology. It combines the specificity of monoclonal antibodies and the sensitivity of fluorescent detection: a tumor specific molecule conjugated to a fluorescent dye is injected to patients. When the patient undergoes surgery, the induced contrast between healthy tissue and tumors allows a precise isolation of tumor nodules that can be resected by the surgeon with no delay.

Not only can surgeons rely on fluorescence imaging to assess surgical margins, but they can also use this tool for cancer staging and detection of metastases that are otherwise too small to be detected.

SurgiMab’s fluorescent conjugates are excited at 700nm, meaning that they can be used together with ICG, the only non-targeted fluorescent dye that is authorized to date in the clinic for near infra-red angiography of blood vessels during reconstructive surgery.